(Q36054863)

11 August 2017

1 reference

title

Mycophenolate mofetil in lupus nephritis. (English)

1 reference

11 August 2017

2

C Aranow

1 reference

11 August 2017

1

E M Ginzler

1 reference

11 August 2017

publication date

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

14

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

59-64

1 reference

Mycophenolate mofetil and its mechanisms of action

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZB x NZW)F1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

The safety and efficacy of MMF in lupus nephritis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

Lupus nephritis: treatment with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

Treatment of lupus nephritis--a work in progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2061OA

10.1191/0961203305LU2061OA

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference